| Literature DB >> 24602313 |
Yasushi Rino1, Norio Yukawa, Tsutomu Sato, Naoto Yamamoto, Hiroshi Tamagawa, Shinichi Hasegawa, Takashi Oshima, Takaki Yoshikawa, Munetaka Masuda, Toshio Imada.
Abstract
BACKGROUND: We thought that using electrocautery for hemostasis caused recurrent laryngeal nerve palsy. We reflected the prolonged use of electrocautery and employed NU-KNIT® to achieve hemostasis nearby the recurrent laryngeal nerve. We assessed that using NU-KNIT® hemostasis prevented or not postoperative recurrent laryngeal nerve palsy, retrospectively. The present study was evaluated to compare using electrocautery hemostasis with using NU-KNIT® hemostasis during lymphadenectomy along recurrent laryngeal nerve. The variables compared were morbidity rate of recurrent laryngeal nerve palsy, operation time, and blood loss.Entities:
Mesh:
Year: 2014 PMID: 24602313 PMCID: PMC3973846 DOI: 10.1186/1756-0500-7-127
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Patients characters and operation datas
| Group E | M | 75 | pT1bN0M0 I | 1249 | 703/286 | y (bilateral) |
| | M | 67 | pT3N1M0 III | 1343 | 500/186 | n |
| | M | 64 | pT3N0M0 II | 669 | 503/198 | y |
| | M | 57 | pT1bN0M0 III | 389 | 518/212 | y (bilateral) |
| | M | 49 | pT4N0M1 IVb | 200 | 379/153 | n |
| | M | 51 | pT3N1M0 III | 100 | 395/210 | n |
| | M | 60 | pT1bN1M0 II | 500 | 476/160 | y |
| | M | 61 | pT3N2M0 III | 600 | 502/235 | y |
| | F | 57 | pT3N0M0 II | 208 | 640/160 | n |
| Average ± S.D. | | 60.1 ± 8.0 | | 584.2 ± 446.4 | 512.9 ± 103.6/200.0 ± 42.5 | Complication rate; 55.6%* |
| Group N | M | 63 | pT2N1M0 II | 795 | 594/220 | n |
| | M | 61 | pT2N0M0 II | 3000 | 660/240 | y |
| | M | 67 | pT3N0M1 IVb | 555 | 429/190 | n |
| | M | 66 | pT1aN0M0 0 | 500 | 499/170 | n |
| | M | 68 | pT3N1M0 III | 691 | 590/235 | n |
| | M | 66 | pT2N2M0 III | 2140 | 513/199 | n |
| | M | 64 | pT3N0M0 II | 250 | 545/264 | n |
| | M | 70 | pT1aN0M0 0 | 765 | 558/281 | n |
| | M | 76 | pT2N0M0 II | 2992 | 472/239 | n |
| | M | 63 | pT1bN0M0 I | 788 | 623/353 | n |
| | M | 72 | pT3N1M0 III | 278 | 466/202 | n |
| | M | 74 | pT1bN0M0 I | 300 | 561/324 | n |
| | F | 74 | pT2N0M0 II | 675 | 355/236 | n |
| | M | 56 | pT3N2M0 III | 100 | 435/195 | n |
| | M | 74 | pT1aN0M0 0 | 319 | 541/284 | n |
| | M | 63 | pT1bN0M0 I | 400 | 508/272 | n |
| | M | 69 | pT3N1M0 III | 757 | 621/273 | n |
| | M | 75 | pT1bN0M0 I | 341 | 708/374 | n |
| | M | 63 | pT1bN0M0 I | 203 | 618/351 | n |
| Average ± S.D | 67.6 ± 5.6 | 834.2 ± 877.9 | 541.9 ± 88.0/258.0 ± 59.3 | Complication rate; 5.3% |
Group E; using electrocautery to achieve hemostasis, Group N; using NU-KNIT® to achieve hemostasis.
M; male, F; female, S.D.; standard deviation, *; p = 0.007.